Phase III study of ramucirumab plus docetaxel versus atezolizumab for PD-L1 negative or weakly positive advanced non-small-cell lung cancer after disease progression on platinum-based therapy; WJOG10317L study (EMERALD)
Docetaxel;Ramucirumab;Atezolizumab
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Phase III study of ramucirumab plus docetaxel versus atezolizumab for PD-L1 negative or weakly positive advanced non-small-cell lung cancer after disease progression on platinum-based therapy; WJOG10317L study (EMERALD) ### Output: Docetaxel;Ramucirumab;Atezolizumab